OTC醫藥品產業：新興國家市場的產業指南 是由出版商MarketLine在2010年11月所出版的。
這份英文市場調查報告書包含Pages: 215 價格從美金995起跳。
Abstract
Datamonitor' s OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary,
Mexico, Poland, South Africa, Taiwan) Industry Guide is an essential resource
for top-level data and analysis covering the OTC Pharmaceuticals industry in
Brazil, Hungary, Mexico, Poland, South Africa, and Taiwan. The report includes
easily comparable data on market value, volume, segmentation and market share
for the advanced emerging markets otc pharmaceuticals markets, plus full
five-year market forecasts. It examines future problems, innovations and
potential growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and
segmentation
* Provides textual analysis of the industry' s prospects, competitive
landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and
scorecards
* Compares data from Brazil, Hungary, Mexico, Poland, South Africa and
Taiwan, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The advanced emerging market countries contributed $8,059.5 million to the
global otc pharmaceuticals industry in 2005, with a compound annual growth
rate (CAGR) of 6.5% between 2005 and 2009 bringing this contribution to
$10,370.4million.
These countries are expected to reach a value of $13,331.5 million in 2014,
with a CAGR of 5.2% over the 2009-14 period.
Brazil holds the major share of the OTC pharmaceutical industry. In 2009, it
accounted for 36.1% of the market.
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market consists of the retail sale of traditional
medicines, cough and cold preparations (tablets, mixtures, lozenges, topical
remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals,
single vitamins, tonics, cod liver oil), indigestion preparations (tablets,
powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other
analgesics), and medicated skin products (anti-bacteria’s, acne
treatments, anti-fungal, disinfectants and other), topical OTC medicines
(anesthetic products, anti-itch products, antibiotic creams/gels), plasters &
bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze,
liquid bandages and other tape or bandage), first aid kits and other
(anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and
motion sickness).
Table of Contents
TABLE OF CONTENTS
INTRODUCTION
What Is This Report About?
Who Is The Target Reader?
Definition
ADVANCED EMERGING MARKETS OTC PHARMACEUTICALS INDUSTRY OUTLOOK
OTC PHARMACEUTICALS IN BRAZIL
Market Overview
Market Value
Market Segmentation I
Market Segmentation Ii
Market Share
Five Forces Analysis
Leading Companies
Market Distribution
Market Forecasts
Macroeconomic Indicators
OTC PHARMACEUTICALS IN HUNGARY
Market Overview
Market Value
Market Segmentation I
Market Segmentation Ii
Market Share
Five Forces Analysis
Leading Companies
Market Distribution
Market Forecasts
Macroeconomic Indicators
OTC PHARMACEUTICALS IN MEXICO
Market Overview
Market Value
Market Segmentation I
Market Segmentation Ii
Market Share
Five Forces Analysis
Leading Companies
Market Distribution
Market Forecasts
Macroeconomic Indicators
OTC PHARMACEUTICALS IN POLAND
Market Overview
Market Value
Market Segmentation I
Market Segmentation Ii
Market Share
Five Forces Analysis
Leading Companies
Market Distribution
Market Forecasts
Macroeconomic Indicators
OTC PHARMACEUTICALS IN SOUTH AFRICA
Market Overview
Market Value
Market Segmentation I
Market Share
Five Forces Analysis
Leading Companies
Market Distribution
Market Forecasts
Macroeconomic Indicators
OTC PHARMACEUTICALS IN TAIWAN
Market Overview
Market Value
Market Segmentation I
Market Segmentation Ii
Market Share
Five Forces Analysis
Leading Companies
Market Distribution
Market Forecasts
Macroeconomic Indicators
APPENDIX
Data Research Methodology
About Datamonitor
Disclaimer
LIST OF TABLES
Table 1: Advanced emerging markets otc pharmaceuticals industry, revenue
($m), 2005-14
Table 2: Advanced emerging markets otc pharmaceuticals industry, revenue by
country ($m), 2005-09
Table 3: Advanced emerging markets otc pharmaceuticals industry forecast,
revenue by country ($m), 2009-14
Table 4: Brazil OTC pharmaceuticals market value: $ million, 2005-09
Table 5: Brazil OTC pharmaceuticals market segmentation I:% share, by value,
2009
Table 6: Brazil OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Table 7: Brazil OTC pharmaceuticals market share: % share, by value, 2009
Table 8: Johnson & Johnson: key facts
Table 9: Johnson & Johnson: key financials ($)
Table 10: Johnson & Johnson: key financial ratios
Table 11: Sanofi-Aventis: key facts
Table 12: Sanofi-Aventis: key financials ($)
Table 13: Sanofi-Aventis: key financials (€)
Table 14: Sanofi-Aventis: key financial ratios
Table 15: Abbott Laboratories: key facts
Table 16: Abbott Laboratories: key financials ($)
Table 17: Abbott Laboratories: key financial ratios
Table 18: Brazil OTC pharmaceuticals market distribution: % share, by value,
2009
Table 19: Brazil OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 20: Brazil size of population (million), 2005-09
Table 21: Brazil gdp (constant 2000 prices, $ billion), 2005-09
Table 22: Brazil gdp (current prices, $ billion), 2005-09
Table 23: Brazil inflation, 2005-09
Table 24: Brazil consumer price index (absolute), 2005-09
Table 25: Brazil exchange rate, 2005-09
Table 26: Hungary OTC pharmaceuticals market value: $ million, 2005-09
Table 27: Hungary OTC pharmaceuticals market segmentation I:% share, by
value, 2009
Table 28: Hungary OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Table 29: Hungary OTC pharmaceuticals market share: % share, by value, 2009
Table 30: Johnson & Johnson: key facts
Table 31: Johnson & Johnson: key financials ($)
Table 32: Johnson & Johnson: key financial ratios
Table 33: Béres Pharmaceuticals Co. Ltd: key facts
Table 34: EGIS Pharmaceuticals Ltd.: key facts
Table 35: EGIS Pharmaceuticals Ltd.: key financials ($)
Table 36: EGIS Pharmaceuticals Ltd.: key financials (HUF)
Table 37: EGIS Pharmaceuticals Ltd.: key financial ratios
Table 38: Hungary OTC pharmaceuticals market distribution: % share, by value,
2009
Table 39: Hungary OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 40: Hungary size of population (million), 2005-09
Table 41: Hungary gdp (constant 2000 prices, $ billion), 2005-09
Table 42: Hungary gdp (current prices, $ billion), 2005-09
Table 43: Hungary inflation, 2005-09
Table 44: Hungary consumer price index (absolute), 2005-09
Table 45: Hungary exchange rate, 2005-09
Table 46: Mexico OTC pharmaceuticals market value: $ million, 2005-09
Table 47: Mexico OTC pharmaceuticals market segmentation I:% share, by value,
2009
Table 48: Mexico OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Table 49: Mexico OTC pharmaceuticals market share: % share, by value, 2009
Table 50: Bayer AG: key facts
Table 51: Bayer AG: key financials ($)
Table 52: Bayer AG: key financials (€)
Table 53: Bayer AG: key financial ratios
Table 54: Johnson & Johnson: key facts
Table 55: Johnson & Johnson: key financials ($)
Table 56: Johnson & Johnson: key financial ratios
Table 57: Boehringer Ingelheim GmbH: key facts
Table 58: Boehringer Ingelheim GmbH: key financials ($)
Table 59: Boehringer Ingelheim GmbH: key financials (€)
Table 60: Boehringer Ingelheim GmbH: key financial ratios
Table 61: Mexico OTC pharmaceuticals market distribution: % share, by value,
2009
Table 62: Mexico OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 63: Mexico size of population (million), 2005-09
Table 64: Mexico gdp (constant 2000 prices, $ billion), 2005-09
Table 65: Mexico gdp (current prices, $ billion), 2005-09
Table 66: Mexico inflation, 2005-09
Table 67: Mexico consumer price index (absolute), 2005-09
Table 68: Mexico exchange rate, 2005-09
Table 69: Poland OTC pharmaceuticals market value: $ million, 2005-09
Table 70: Poland OTC pharmaceuticals market segmentation I:% share, by value,
2009
Table 71: Poland OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Table 72: Poland OTC pharmaceuticals market share: % share, by value, 2009
Table 73: GlaxoSmithKline Plc: key facts
Table 74: GlaxoSmithKline Plc: key financials ($)
Table 75: GlaxoSmithKline Plc: key financials (£)
Table 76: GlaxoSmithKline Plc: key financial ratios
Table 77: US Pharmacia: key facts
Table 78: Herbapol Wroclaw SA: key facts
Table 79: Poland OTC pharmaceuticals market distribution: % share, by value,
2009
Table 80: Poland OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 81: Poland size of population (million), 2005-09
Table 82: Poland gdp (constant 2000 prices, $ billion), 2005-09
Table 83: Poland gdp (current prices, $ billion), 2005-09
Table 84: Poland inflation, 2005-09
Table 85: Poland consumer price index (absolute), 2005-09
Table 86: Poland exchange rate, 2005-09
Table 87: South Africa OTC pharmaceuticals market value: $ million,
2005-09
Table 88: South Africa OTC pharmaceuticals market segmentation I:% share, by
value, 2009
Table 89: South Africa OTC pharmaceuticals market share: % share, by value,
2009
Table 90: Pharma Natura (Pty) Ltd: key facts
Table 91: Weleda Group: key facts
Table 92: Johnson & Johnson: key facts
Table 93: Johnson & Johnson: key financials ($)
Table 94: Johnson & Johnson: key financial ratios
Table 95: South Africa OTC pharmaceuticals market distribution: % share, by
value, 2009
Table 96: South Africa OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 97: South Africa size of population (million), 2005-09
Table 98: South Africa gdp (constant 2000 prices, $ billion), 2005-09
Table 99: South Africa gdp (current prices, $ billion), 2005-09
Table 100: South Africa inflation, 2005-09
Table 101: South Africa consumer price index (absolute), 2005-09
Table 102: South Africa exchange rate, 2005-09
Table 103: Taiwan OTC pharmaceuticals market value: $ million, 2005-09
Table 104: Taiwan OTC pharmaceuticals market segmentation I:% share, by
value, 2009
Table 105: Taiwan OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Table 106: Taiwan OTC pharmaceuticals market share: % share, by value, 2009
Table 107: China Chemical and Pharmaceutical Co., Ltd.: key facts
Table 108: China Chemical and Pharmaceutical Co., Ltd.: key financials ($)
Table 109: China Chemical and Pharmaceutical Co., Ltd.: key financials (NT$)
Table 110: China Chemical and Pharmaceutical Co., Ltd.: key financial ratios
Table 111: Sinphar pharmaceuticals co ltd: key facts
Table 112: Sinphar pharmaceuticals co ltd: key financials ($)
Table 113: Sinphar pharmaceuticals co ltd: key financials (NT$)
Table 114: Sinphar pharmaceuticals co ltd: key financial ratios
Table 115: Daiichi Sankyo, Ltd.: key facts
Table 116: Daiichi Sankyo, Ltd.: key financials ($)
Table 117: Daiichi Sankyo, Ltd.: key financials (¥)
Table 118: Daiichi Sankyo, Ltd.: key financial ratios
Table 119: Taiwan OTC pharmaceuticals market distribution: % share, by value,
2009
Table 120: Taiwan OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 121: Taiwan size of population (million), 2005-09
Table 122: Taiwan gdp (constant 2000 prices, $ billion), 2005-09
Table 123: Taiwan gdp (current prices, $ billion), 2005-09
Table 124: Taiwan inflation, 2005-09
Table 125: Taiwan consumer price index (absolute), 2005-09
Table 126: Taiwan exchange rate, 2005-09
LIST OF FIGURES
Figure 1: Advanced emerging markets otc pharmaceuticals industry, revenue
($m), 2005-14
Figure 2: Advanced emerging markets otc pharmaceuticals industry, country
analysis (%), 2005-14
Figure 3: Advanced emerging markets otc pharmaceuticals industry, revenue by
country ($m), 2005-09
Figure 4: Advanced emerging markets otc pharmaceuticals industry forecast,
revenue by country ($m), 2009-14
Figure 5: Brazil OTC pharmaceuticals market value: $ million, 2005-09
Figure 6: Brazil OTC pharmaceuticals market segmentation I:% share, by value,
2009
Figure 7: Brazil OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Figure 8: Brazil OTC pharmaceuticals market share: % share, by value, 2009
Figure 9: Forces driving competition in the OTC pharmaceuticals market in
Brazil, 2009
Figure 10: Drivers of buyer power in the OTC pharmaceuticals market in
Brazil, 2009
Figure 11: Drivers of supplier power in the OTC pharmaceuticals market in
Brazil, 2009
Figure 12: Factors influencing the likelihood of new entrants in the OTC
pharmaceuticals market in Brazil, 2009
Figure 13: Factors influencing the threat of substitutes in the OTC
pharmaceuticals market in Brazil, 2009
Figure 14: Drivers of degree of rivalry in the OTC pharmaceuticals market in
Brazil, 2009
Figure 15: Johnson & Johnson: revenues & profitability
Figure 16: Johnson & Johnson: assets & liabilities
Figure 17: Sanofi-Aventis: revenues & profitability
Figure 18: Sanofi-Aventis: assets & liabilities
Figure 19: Abbott Laboratories: revenues & profitability
Figure 20: Abbott Laboratories: assets & liabilities
Figure 21: Brazil OTC pharmaceuticals market distribution: % share, by value,
2009
Figure 22: Brazil OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 23: Hungary OTC pharmaceuticals market value: $ million, 2005-09
Figure 24: Hungary OTC pharmaceuticals market segmentation I:% share, by
value, 2009
Figure 25: Hungary OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Figure 26: Hungary OTC pharmaceuticals market share: % share, by value, 2009
Figure 27: Forces driving competition in the OTC pharmaceuticals market in
Hungary, 2009
Figure 28: Drivers of buyer power in the OTC pharmaceuticals market in
Hungary, 2009
Figure 29: Drivers of supplier power in the OTC pharmaceuticals market in
Hungary, 2009
Figure 30: Factors influencing the likelihood of new entrants in the OTC
pharmaceuticals market in Hungary, 2009
Figure 31: Factors influencing the threat of substitutes in the OTC
pharmaceuticals market in Hungary, 2009
Figure 32: Drivers of degree of rivalry in the OTC pharmaceuticals market in
Hungary, 2009
Figure 33: Johnson & Johnson: revenues & profitability
Figure 34: Johnson & Johnson: assets & liabilities
Figure 35: EGIS Pharmaceuticals Ltd.: revenues & profitability
Figure 36: EGIS Pharmaceuticals Ltd.: assets & liabilities
Figure 37: Hungary OTC pharmaceuticals market distribution: % share, by
value, 2009
Figure 38: Hungary OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 39: Mexico OTC pharmaceuticals market value: $ million, 2005-09
Figure 40: Mexico OTC pharmaceuticals market segmentation I:% share, by
value, 2009
Figure 41: Mexico OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Figure 42: Mexico OTC pharmaceuticals market share: % share, by value, 2009
Figure 43: Forces driving competition in the OTC pharmaceuticals market in
Mexico, 2009
Figure 44: Drivers of buyer power in the OTC pharmaceuticals market in
Mexico, 2009
Figure 45: Drivers of supplier power in the OTC pharmaceuticals market in
Mexico, 2009
Figure 46: Factors influencing the likelihood of new entrants in the OTC
pharmaceuticals market in Mexico, 2009
Figure 47: Factors influencing the threat of substitutes in the OTC
pharmaceuticals market in Mexico, 2009
Figure 48: Drivers of degree of rivalry in the OTC pharmaceuticals market in
Mexico, 2009
Figure 49: Bayer AG: revenues & profitability
Figure 50: Bayer AG: assets & liabilities
Figure 51: Johnson & Johnson: revenues & profitability
Figure 52: Johnson & Johnson: assets & liabilities
Figure 53: Boehringer Ingelheim GmbH: revenues & profitability
Figure 54: Boehringer Ingelheim GmbH: assets & liabilities
Figure 55: Mexico OTC pharmaceuticals market distribution: % share, by value,
2009
Figure 56: Mexico OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 57: Poland OTC pharmaceuticals market value: $ million, 2005-09
Figure 58: Poland OTC pharmaceuticals market segmentation I:% share, by
value, 2009
Figure 59: Poland OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Figure 60: Poland OTC pharmaceuticals market share: % share, by value, 2009
Figure 61: Forces driving competition in the OTC pharmaceuticals market in
Poland, 2009
Figure 62: Drivers of buyer power in the OTC pharmaceuticals market in
Poland, 2009
Figure 63: Drivers of supplier power in the OTC pharmaceuticals market in
Poland, 2009
Figure 64: Factors influencing the likelihood of new entrants in the OTC
pharmaceuticals market in Poland, 2009
Figure 65: Factors influencing the threat of substitutes in the OTC
pharmaceuticals market in Poland, 2009
Figure 66: Drivers of degree of rivalry in the OTC pharmaceuticals market in
Poland, 2009
Figure 67: GlaxoSmithKline Plc: revenues & profitability
Figure 68: GlaxoSmithKline Plc: assets & liabilities
Figure 69: Poland OTC pharmaceuticals market distribution: % share, by value,
2009
Figure 70: Poland OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 71: South Africa OTC pharmaceuticals market value: $ million,
2005-09
Figure 72: South Africa OTC pharmaceuticals market segmentation I:% share, by
value, 2009
Figure 73: South Africa OTC pharmaceuticals market share: % share, by value,
2009
Figure 74: Forces driving competition in the OTC pharmaceuticals market in
South Africa, 2009
Figure 75: Drivers of buyer power in the OTC pharmaceuticals market in South
Africa, 2009
Figure 76: Drivers of supplier power in the OTC pharmaceuticals market in
South Africa, 2009
Figure 77: Factors influencing the likelihood of new entrants in the OTC
pharmaceuticals market in South Africa, 2009
Figure 78: Factors influencing the threat of substitutes in the OTC
pharmaceuticals market in South Africa, 2009
Figure 79: Drivers of degree of rivalry in the OTC pharmaceuticals market in
South Africa, 2009
Figure 80: Johnson & Johnson: revenues & profitability
Figure 81: Johnson & Johnson: assets & liabilities
Figure 82: South Africa OTC pharmaceuticals market distribution: % share, by
value, 2009
Figure 83: South Africa OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 84: Taiwan OTC pharmaceuticals market value: $ million, 2005-09
Figure 85: Taiwan OTC pharmaceuticals market segmentation I:% share, by
value, 2009
Figure 86: Taiwan OTC pharmaceuticals market segmentation II: % share, by
value, 2009
Figure 87: Taiwan OTC pharmaceuticals market share: % share, by value, 2009
Figure 88: Forces driving competition in the OTC pharmaceuticals market in
Taiwan, 2009
Figure 89: Drivers of buyer power in the OTC pharmaceuticals market in
Taiwan, 2009
Figure 90: Drivers of supplier power in the OTC pharmaceuticals market in
Taiwan, 2009
Figure 91: Factors influencing the likelihood of new entrants in the OTC
pharmaceuticals market in Taiwan, 2009
Figure 92: Factors influencing the threat of substitutes in the OTC
pharmaceuticals market in Taiwan, 2009
Figure 93: Drivers of degree of rivalry in the OTC pharmaceuticals market in
Taiwan, 2009
Figure 94: China Chemical and Pharmaceutical Co., Ltd.: revenues &
profitability
Figure 95: China Chemical and Pharmaceutical Co., Ltd.: assets & liabilities
Figure 96: Sinphar pharmaceuticals co ltd: revenues & profitability
Figure 97: Sinphar pharmaceuticals co ltd: assets & liabilities
Figure 98: Daiichi Sankyo, Ltd.: revenues & profitability
Figure 99: Daiichi Sankyo, Ltd.: assets & liabilities
Figure 100: Taiwan OTC pharmaceuticals market distribution: % share, by
value, 2009
Figure 101: Taiwan OTC pharmaceuticals market value forecast: $ million,
2009-14
